Bank of New York Mellon »

Sab Biotherapeutics shares owned by Bank of New York Mellon

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Bank of New York Mellon from 13F filings

Historical chart of Bank of New York Mellon investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Bank of New York Mellon consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Bank of New York Mellon

Quarter filed Position value Share count Share price at filing
2026-06-30 $421k 108k 3.90

More positions owned by Bank of New York Mellon

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Inc-cl A Cap (GOOGL)
Broadcom (AVGO)
Ishares Core S&p 500 Etf Core (IVV)
Alphabet Inc-cl C Cap (GOOG)
Micron Technology (MU)
Meta Platforms Inc-class A Cl A (META)
JPMorgan Chase & Co. (JPM)
Tesla Motors (TSLA)
Advanced Micro Devices (AMD)
Eli Lilly & Co. (LLY)
Johnson & Johnson (JNJ)

View all positions for Bank of New York Mellon

Top funds holding Sab Biotherapeutics

Caligan Partners
Vivo Capital
Perceptive Advisors
Adage Capital Partners GP
RA Capital Management
Balyasny Asset Management
BlackRock
Vanguard Capital Management
Commodore Capital
Millennium Management
Spruce Street Capital
Sessa Capital IM
Affinity Asset Advisors
Boothbay Fund Management
Geode Capital Management

View all funds holding Sab Biotherapeutics